Revision Process for Global/National Pharmacopoeias (eBook)
This article describes the revision process and the resulting publication of proposed and official updates for pharmacopoeias around the world.
Pharmacopoeia Compliance Series
Compliance with requirements published by pharmacopoeias around the world is a legal and regulatory requirement for drug companies seeking to market products in that region. The multiple pharmacopoeias around the world are frequently revised and expanded, presenting challenges for bio/pharmaceutical companies that must monitor this activity. This article examines the revision process of global and national pharmacopoeias, the publication schedules, and describes differences between the procedures of the various authorities.
This article is part of a series that will be published in 2019–2020. View all articles in this series.
Read this article in BioPharm International’s December 2019 Regulatory Sourcebook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 14–24
Citation
When referring to this article, please cite it as J.M. Wiggins and J.A. Albanese, “Revision Process for Global/National Pharmacopoeias," BioPharm International Sourcebook eBook (December 2019).
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
